Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00478647
Status:
COMPLETED
Last Update Posted:
2021-06-10
First Post:
2007-05-23
Brief Title:
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Multicenter Open-Label Study of Gene-Activated Human Glucocerebrosidase GA-GCB Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase GCB Due to the deficiency of functional GCB glucocerebroside accumulates within macrophages leading to cellular engorgement organomegaly and organ system dysfunction The purpose of this study is to evaluate the safety and efficacy of every other week dosing of GA-GCB velaglucerase alfa in participants with type 1 Gaucher disease who were previously treated with imiglucerase
Detailed Description:
Type 1 Gaucher disease the most common form accounts for more than 90 of all cases and does not involve the CNS Typical manifestations of type 1 Gaucher disease include hepatomegaly splenomegaly thrombocytopenia bleeding tendencies anemia hypermetabolism skeletal pathology growth retardation pulmonary disease and decreased quality of life Gene-Activated human glucocerebrosidase GA-GCB velaglucerase alfa is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme GA-GCB contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease This study was designed to determine the safety of GA-GCB in men women and children with Type 1 Gaucher disease who were previously treated with imiglucerase Each participants duration of treatment will be 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-006304-11 | EUDRACT_NUMBER | None | None |